Status:
COMPLETED
Prediction of Tumor Shrinkage in Acromegaly
Lead Sponsor:
Federico II University
Conditions:
Acromegaly
Eligibility:
All Genders
18-85 years
Brief Summary
In the last two decades, somatostatin analogs have become a cornerstone of medical therapy for acromegaly. One year of treatment with octreotide-LAR (LAR) controls GH and IGF-I excess in 54% and 63% o...
Detailed Description
From Jan 1st 1995 to December 31st 2006, all files of patients with newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment ...
Eligibility Criteria
Inclusion
- No previous treatment for acromegaly
Exclusion
- primary surgery
- concomitant hyperprolactinemia requiring combined somatostatin analogues and dopamine-agonist treatment
- primary treatment with lanreotide
Key Trial Info
Start Date :
January 1 1997
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00616408
Start Date
January 1 1997
End Date
December 1 2007
Last Update
February 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Italy, 80131